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Background: Subterranean blind mole rats (Spalax) are hypoxia tolerant (down to 3% O2), long lived (>20 years)
rodents showing no clear signs of aging or aging related disorders. In 50 years of Spalax research, spontaneous
tumors have never been recorded among thousands of individuals. Here we addressed the questions of (1)
whether Spalax is resistant to chemically-induced tumorigenesis, and (2) whether normal fibroblasts isolated from
Spalax possess tumor-suppressive activity.
Results: Treating animals with 3-Methylcholantrene (3MCA) and 7,12-Dimethylbenz(a) anthracene/
12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA), two potent carcinogens, confirmed Spalax high resistance to
chemically induced cancers. While all mice and rats developed the expected tumors following treatment with both
carcinogens, among Spalax no tumors were observed after DMBA/TPA treatment, while 3MCA induced benign
fibroblastic proliferation in 2 Spalax individuals out of12, and only a single animal from the advanced age group
developed malignancy 18 months post-treatment. The remaining animals are still healthy 30 months
post-treatment. In vitro experiments showed an extraordinary ability of normal Spalax cultured fibroblasts to restrict
malignant behavior in a broad spectrum of human-derived and in newly isolated Spalax 3MCA-induced cancer cell
lines. Growth of cancer cells was inhibited by either direct interaction with Spalax fibroblasts or with soluble factors
released into culture media and soft agar. This was accompanied by decreased cancer cell viability, reduced colony
formation in soft agar, disturbed cell cycle progression, chromatin condensation and mitochondrial fragmentation.
Cells from another cancer resistant subterranean mammal, the naked mole rat, were also tested for direct effect on
cancer cells and, similar to Spalax, demonstrated anti-cancer activity. No effect on cancer cells was observed using
fibroblasts from mouse, rat or Acomys. Spalax fibroblast conditioned media had no effect on proliferation of
noncancerous cells.
Conclusions: This report provides pioneering evidence that Spalax is not only resistant to spontaneous cancer but
also to experimentally induced cancer, and shows the unique ability of Spalax normal fibroblasts to inhibit growth
and kill cancer cells, but not normal cells, either through direct fibroblast-cancer cell interaction or via soluble
factors. Obviously, along with adaptation to hypoxia, Spalax has evolved efficient anti-cancer mechanisms yet to be
elucidated. Exploring the molecular mechanisms allowing Spalax to survive in extreme environments and to escape
cancer as well as to kill homologous and heterologous cancer cells may hold the key for understanding the
molecular nature of host resistance to cancer and identify new anti-cancer strategies for treating humans.* Correspondence: aaron@research.haifa.ac.il; Imad.Shams@univ.haifa.ac.il
†Equal contributors
1Institute of Evolution, University of Haifa, Haifa 31095, Israel
Full list of author information is available at the end of the article
© 2013 Manov et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Manov et al. BMC Biology 2013, 11:91 Page 2 of 17
http://www.biomedcentral.com/1741-7007/11/91Background
Throughout the last 50 years, several thousand Spalax
individuals have been housed and studied in the Animal
Facility at the Institute of Evolution of Haifa University.
Despite this small rodent’s (approximately 100 to 200 gr.)
long lifespan (>20 years), none of the animals have ever
developed spontaneous tumors, nor do they show any
aging-related phenotypic changes. The mole rat, Spalax
ehrenbergi, is a wild, solitary rodent of the Eastern
Mediterranean region. Spalax inhabits a system of poorly
ventilated, dark, sealed underground tunnels protected
from climatic extremes, pathogens and predation. During
the Mediterranean rainy season animals are engaged in in-
tensive digging to collect food, mate, and repair and extend
their territory under extreme hypoxic conditions. Spalax
has evolved a unique adaptive complex mechanism for
surviving underground, including a special ability to
cope with extreme hypoxia and hypercapnia [1]. Spalax can
conduct intensive aerobic work under low O2 pressures
(down to 3% O2) due to increased muscular mass, and high
density of blood vessels and mitochondria, resulting in
reduced oxygen diffusion distance and efficient oxygen
delivery even at low capillary PO2 [1,2].
Hypoxia can result in a failure to maintain essential
cellular functions and contributes to cardio- and cerebro-
vascular failure, pulmonary diseases and cancer, which to-
gether are the primary sources of morbidity in the Western
world. A long and growing list of genes exhibits hypoxia-
related adaptations in structure and function in Spalax
[3-6]. Noteworthy are VEGF, constitutively highly expressed
as compared to rats [7]; p53 that harbors substitutions in
the DNA-binding site, identical to the most common p53
mutations in tumors; however, in Spalax it renders a
bias against apoptosis but favors cell cycle arrest/DNA
repair both in vitro and in vivo [8]; and a unique Spalax
heparanase splice variant that was shown to decrease
tumor size in mice by a factor of 7 and reduce metastatic
activity compared to native mice heparanase [9]. Further-
more, assessment of Spalax transcriptome assembly and
expression data has revealed enrichment of genes that
overlap cancer resistance, apoptosis, angiogenesis pathways
and hypoxia-tolerance [10,11]. This suggests that Spalax is
potentially resistant to malignant transformation. Elucidat-
ing the mechanisms evolved in this wild, non-inbred, natur-
ally cancer resistant rodent should have great importance
as preventative measures and may present an efficient way
of dealing with increasing cancer incidence.
Tumors contain malignant cells and tumor stroma
consisting of fibroblasts, extracellular matrix (ECM)
and vasculature with endothelial cells [12,13]. Cancer
progression requires a permissive stromal environment in
which mutant cells can survive, proliferate and invade.
Fibroblasts are ubiquitous stromal cells interlinked with
tumors via regulation of growth factors and cytokines,and through reassembling of the ECM [14]. The majority
of published studies report the cancer-enhancing effects
of fibroblasts in their activated form [15,16]. However,
early studies from co-culture experiments indicate that
normal fibroblasts may have a tumor suppressor function
[16]. Unfortunately, little attention has been given to the
protective role of normal fibroblasts.
Based on our earlier observations that Spalax is resistant
to spontaneous cancer, and assuming that normal fibro-
blasts apparently play a role in this phenomenon, we took
two experimental approaches in the present study: (1)
to directly confirm the hypothesis that Spalax is highly
resistant to induced tumorigenesis, we used a two-step 7,12-
Dimethylbenz (a) anthracene/12-O-tetradecanoylphorbol-
13-acetate (DMBA/TPA) skin carcinogenesis protocol [17],
and 3-Methylcholantrene (3MCA) protocol for local fibro-
sarcoma induction [18] in mice, rats and Spalax; and (2)
co-culture experiments were conducted to study the in-
teractions between normal primary fibroblasts isolated
from different rodent species (Spalax, mouse, rat, naked
mole rat Heterocephalus glaber and spiny mice Acomys
cahirinus), with human hepatocellular carcinoma (Hep3B
and HepG2) and breast cancer cells (MDA-MB-231
and MCF7), as well as 3MCA-induced, Spalax-derived
fibrosarcoma cells (SpFS2240).
We provide evidence that (1) Spalax is extremely resist-
ant to experimentally induced cancer, and (2) Spalax’s nor-
mal fibroblasts, originated from adult or newborn animals,
target tumor cells and restrict malignant behavior either
through direct fibroblast-cancer cell interaction or via sol-
uble factors produced by a monolayer of Spalax fibroblasts.
Results
Spalax is resistant to chemically-induced cancer
To assess experimentally if Spalax is resistant to chemically-
induced carcinogenesis, we treated animals from different
rodent species according to the following protocols:
DMBA/TPA treatment
Spalax and C57BL/6 mice were treated with DMBA/TPA
to induce skin cancer [19]. Spalax animals developed skin
lesions within 10 days (Figure 1A, upper middle panel).
Histological examination of hematoxylin and eosin-stained
tissue sections demonstrated skin necrosis involving the
deep parts of the dermis, massive infiltration of the affected
areas with neutrophil leukocytes, and ulcerated epidermis
focally covered with fibrino-purulent exudates (Figure 1A,
lower middle panel). The subcutaneous skeletal muscle and
bone tissues were not affected, and no tumor was identified.
The wounds completely healed within seven to nine weeks,
resulting in epidermal thickening (Figure 1A, right panels),
and no further progression to skin tumors was observed,
even though TPA treatments were extended to six months
(November 2010 to April 2011). In the control group,
Figure 1 Effect of DMBA/TPA carcinogenic applications on Spalax and mice skin. Macroscopic and microscopic skin changes in Spalax
(A) and mice (B). (A) Normal tissues (left images). Necrosis of skin and subcutaneous adipose tissue (middle images). Completely healed skin lesion
showing epidermal thickening with hyperkeratosis and dermal fibrosis (right images). Hematoxylin and eosin staining, ×40 (left and middle images)
and ×100 (right image). (B) Normal tissues (left images). Intra-epidermal blisters, partially ruptured with erosion formation and crusting, congestion and
inflammatory cell infiltrate within the dermis indicate ongoing inflammation (middle images). Skin papillary outgrowths with thickened, dysplastic
epidermis, numerous mitoses and foci are suggestive of squamous cell carcinoma (right image). Hematoxylin and eosin staining, ×40
(left and middle images) and ×100 (right image). DMBA/TPA, 7,12-Dimethylbenz(a) anthracene/12-O-tetradecanoylphorbol-13-acetate.
Manov et al. BMC Biology 2013, 11:91 Page 3 of 17
http://www.biomedcentral.com/1741-7007/11/91Spalax animals treated with acetone only did not show
any changes in their skin macro- and microstructure,
similar to non-treated animals (Figure 1A, left panels).
Following 7 to 10 days of DMBA/TPA treatment, mice
demonstrated small intra-epidermal blisters; some of them
ruptured, forming superficial erosions with extensive
crusting (Figure 1B, middle panels), which subsequently
underwent transformation into multiple skin tumors within
two to three months (Figure 1B, upper right panel). Histo-
logical examination revealed papillary and flat epidermal
outgrowths with dysplastic features, focally similar to
squamous cell carcinoma (Figure 1B, right panels).
3-MCA treatment
The ability of a single subcutaneous 3-MCA injection to
induce fibrosarcoma is well documented [20]. The expected
tumors appeared within two to three months in mice, and
in four to six months in rats. Hypercellular spindle cell
tumors with highly pleiomorphic, extensively proliferating
cells (30 and more mitotic figures per 10 high power fields)
arranged into intersected bundles or wide sheets were
identified. Scant, partially myxoid stroma and areas of
hemorrhagic necrosis were typical findings (Figure 2A).
All examined tumors developed in 3-MCA-treated mice
and rats were histologically identified as fibrosarcomas.
Importantly, Spalax did not show any pathological process
for over a year. However, by 14 to 16 months following the
3-MCA treatment, 2 of the Spalax animals (out of 6 old
individuals and a total of 12 animals) developed a tissue
overgrowth at the site of the injection. These lesions
were well circumscribed in shape, unlike the ill-definedtumors found in mice and rats (Figure 2B). Histological
examination revealed benign spindle cell proliferation
most probably reflecting fibrosis at the site of an incom-
pletely resolved inflammatory reaction.
A case of fibrosarcoma development in Spalax
A single, old Spalax individual developed a 3-MCA-induced
tumor 18 months after initial treatment (Figure 3). A biopsy
was performed, and the histological examination revealed a
partially necrotic and heavily inflamed, spindle and epitheli-
oid cell tumor with infiltrative borders and myxoid stroma.
Cells demonstrated dyscohesion, polymorphism in size and
shape (bizarre and giant cells present) and prominent
nuclear atypia (Figure 3A). This hypercellular tumor
demonstrated high mitotic activity (above 30 mitoses
per 10 high power fields) with abundant atypical mi-
totic figures. Transmission electron microscopy revealed
fibrosarcoma-like findings [21]: deformed nuclei, some
with monstrous appearance; long branching and dilated
rough endoplasmic reticulum and abundance of extra-
cellular collagen fibers (Figure 3B,C). Myofibroblastic
differentiation features were not observed. An immor-
tal cell line was established from the tumor sample.
The cultured adherent cells show a typical fibroblast
phenotype (Figure 3D), which has remained unchanged
throughout a long culture time (40 passages, 8 months
after isolation).
The remaining treated Spalax individuals showed no
phenotypic or behavioral changes, and were still under
observation in the Animal House over two years following
treatment (October 2010 to July 2013).
Figure 2 Effect of 3-Methylcholantren treatment on soft tissue tumor induction in Spalax and mice. Animals treated with a single
injection of 3MCA as described in the Materials and methods section. Representative images show macroscopic and microscopic observations.
Mice (A): An ill-defined, soft mass, with foci of necrosis and hemorrhage; diagnosed as high-grade fibrosarcoma by histology. Spalax (B): a
well-circumscribed, firm, whitish nodule composed of benign spindle cells organized into long regular bundles - benign reactive fibrosis.
Hematoxylin and eosin staining, ×100. 3MCA, 3-Methylcholantrene.
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in vitro
To compare the effects of normal fibroblasts isolated
from different rodents on the growth of human cancer
cells, we used a co-culture approach, where fibroblasts
were cultured together with cancer cells on a shared
surface (Figures 4 and 5). In these experiments, hepatoma-
derived Hep3B cells as well as breast cancer MCF7 cells
were tested. Obvious inhibition of cancer cell growth
was found when Hep3B cells were co-cultured with
Spalax normal lung and skin fibroblasts: the foci of
destroyed cancer cells were visible after six days ofFigure 3 3MCA-induced tumor in Spalax. (A) Light microscopic examina
(empty arrow); nuclei are variable in shape, size and chromatin distribution
(B) Transmission electron microscopy (TEM): dilated, elongated rough endo
(white arrows) (C) TEM: a giant, monstrous nucleus (N). (D) Cell line establi
continuous cultivation (×200). 3MCA, 3-Methylcholantrene.co-culture (Figure 4). Prolonged co-cultivation up to 11
days resulted in further destruction of cancer cell colonies
by the presence of Spalax fibroblasts and the spaces previ-
ously occupied by Hep3B cells were invaded by fibroblasts
(Figure 4). In contrast, the number of cancer cells co-
cultured with mouse fibroblasts increased gradually, and
on Day 6, Hep3B cells surrounded by mouse fibroblasts
reached approximately 80% confluence, similar to control
(Hep3B only). Overgrown Hep3B colonies were found
after 11-day co-culture with mouse fibroblasts. An obvi-
ous inhibitory effect was demonstrated when Spalax nor-
mal skin fibroblasts were co-cultured with breast cancertion. Note spindle, epithelioid and giant multinuclear cells
; nucleoli vary in frequency. Hematoxylin and eosin staining, ×100.
plasmic reticulum (black arrows) and abundant collagen fibers
shed from Spalax tumor, phase contrast image after six months of
Figure 4 Effects of Spalax and mouse fibroblasts on growth of co-cultured human hepatoma cells. Tumor cells (TC) were cultured either
alone or in the presence of Spalax or mouse fibroblasts in the ratio of 1:10 (5 × 104 fibroblasts and 5 × 103 cancer cells in six-well plates) in
RPMI/DMEM-F12 media (1:1) containing 10% FBS. White arrows point to the foci of destroyed cancer cells, and black arrows show the
fibroblast-tumor cell colony boundaries. Cells in mono- and co-cultures were observed and photographed daily. Representative images for each
sample at different time intervals are shown (×200).
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with Spalax fibroblasts, massive rounding and detach-
ment of cancer cells were observed. On the other hand,
mouse fibroblasts stimulated proliferation of MCF7
cells, and by Day 10 densely populated colonies of cancer
cells developed.
In vitro anticancer activity by other wild, natural rodents’
fibroblasts
Since we compare a wild mammal with laboratory ani-
mals that are sensitive to cancer, we conducted co-cultureexperiments using Hep3B cancer cells with skin fibro-
blasts isolated from two different wild, natural rodents:
Acomys, a short-lived, wild, above-ground rodent; and
naked mole rat (Heterocephalus glaber), a long-lived
cancer-resistant wild subterranean rodent [22]. As shown
(Figure 6), no growth inhibitory effect was found when
Acomys fibroblasts were co-cultured with Hep3B cells.
On the contrary, Acomys fibroblasts promoted cancer
cell invasion similar to the effect of rat fibroblasts.
Heterocephalus cells, similar to Spalax, evidently destroyed
cancer cell growth (Figure 6).
Figure 5 Morphologic alterations in human breast cancer MCF7 cells triggered by co-culture with Spalax fibroblasts. MCF7 cells were
co-cultured with skin fibroblasts of Spalax or mouse in the ratio of 1:15 (5 × 104 fibroblasts and 2.5 × 103 cancer cells in six-well plates) in
DMEM/DMEM-F12 media (1:1) containing 5% FBS. Representative phase contrast images after 10 days of co-culture are presented (×200). Note
rounding and detachment of MCF7 cells co-cultured with Spalax fibroblasts. Black arrows point to rounding cells. White arrows show shrunken
“floating” cells.
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induces cancer cell death, but does not affect normal
primary fibroblasts
To determine whether the anti-cancer activity of Spalax
fibroblasts was mediated by fibroblast-secreted soluble
factors, conditioned media (CM) obtained from Spalax,
mouse and rat monolayers were tested. Cancer cells of
different origins were incubated under CM of normal
fibroblasts, which had never been exposed to cancer cells
or other stimuli. Effects of CM generated by cancer cells
were also tested (Figure 7). As demonstrated in Figure 7A,
exposure of Hep3B cells to CM from cultured newborn
Spalax fibroblasts decreased cancer cell viability as mea-
sured by mitochondrial respiratory function. Exposure to
mouse CM hardly had an effect on cancer cell viability.
Similarly, nine-day exposure of Hep3B cells to CM gener-
ated by adult (>5.5 years old) Spalax fibroblasts obviously
reduced cancer cell viability as was determined by a trypan
blue extrusion assay (Figure 7B,C): cancer cells exposed to
Spalax fibroblast-conditioned CM reached 49% death,
whereas unexposed cells remained completely adherent
and viable (Figure 7C).
We next evaluated the reversibility of the inhibition of
cancer cells initiated by Spalax CM. HepG2 and Hep3B
were grown with Spalax CM for four days, then the
medium was changed by either fresh unused regular
media or with fresh Spalax CM. Cancer cell viability
was measured after another two days. Recovery of the
cancer cells was demonstrated when the CM was changed
with fresh unused regular media (Figure 7D). Importantly,
growth of Spalax-derived fibrosarcoma cells (SpFS2240)
was gradually suppressed by CM generated by Spalaxnormal fibroblasts, but was not affected by normal, full
medium and CM derived from Hep3B cells or CM derived
from the SpFS2240 cells themselves (Figure 7E). Note-
worthy, no inhibitory effects were detected on mouse,
rat and Spalax normal fibroblasts following exposure
to homologous or heterologous CM (Figure 7F). To get
a preliminary idea of the nature of the secreted factors
responsible for cancer cell growth inhibition, CM from
Spalax and rat fibroblasts, and the regular medium
of fibroblasts (DMEM-F12) were heated to 56°C for 10
minutes, and 30 minutes. The different heat-treated
media was mixed 1:1 with RPMI (the optimal growth
medium for the hepatoma cell lines used in this study)
and was added to Hep3B cancer cells. After seven days,
the viability of the cancer cells was measured. The
heat-treated CM generated from Spalax fibroblasts reduced
its anticancer activity, expressed as a partial increase in
Hep3B cells viability (Figure 7G).
Soluble factors generated by Spalax fibroblasts cause cell
cycle arrest, nuclear fragmentation, and impair
mitochondrial dynamics in cancer cells
To investigate the mechanisms by which Spalax fibroblasts
induce cancer cell death, we examined nuclear and
mitochondrial shape dynamics, as well as cell cycle dis-
tributions in Hep3B and HepG2 cells. No changes in the
morphology of cells, nuclei and mitochondria as well as
in cell cycle distribution were found when Hep3B cells
were incubated with rat CM (Figure 8, middle row)
compared to Hep3B grown with their own medium
(Figure 8, upper row; control). In contrast, following ex-
posure to Spalax CM, Hep3B cells undergo phenotypic
Figure 6 Comparison of the effects of Spalax, Acomys,
Heterocephalus and rat skin fibroblasts on growth of Hep3B
cells. Hep3B tumor cells were cultured either alone or in presence
of Spalax, Acomys, Heterocephalus or rat fibroblasts in the ratio of
1:10 (5 × 104 fibroblasts and 5 × 103 cancer cells in six-well plates) in
RPMI/DMEM-F12 media (1:1) containing 10% FBS. After seven days
incubation cells were photographed. Representative images for each
sample are shown (×200). White arrows point to the foci of
damaged cancer cells. TC, tumor cells.
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lar shrinkage, irregularities in the plasma membrane and
blebs formation (Figure 8, lower row, phase-contrast).
Cell cycle analysis revealed a noticeable accumulation of
dead cells in sub-G1 (36.7% versus 16.4% in control), a
reduction in the number of cells in G0/G1 (28.9% versus
49.6% in control), and a modest arrest of proliferation in
G2/M (21.7% versus 17.1% in control) (Figure 8, lower
row, cell cycle). Nuclear staining with DAPI of Hep3B
cells that were grown with Spalax CM for eight days,
revealed heterogeneous chromatin appearance within
irregularly shaped nuclei, and in many cells extensive
chromatin condensation and nuclear fragmentation were
conspicuous (Figure 8, lower row, DAPI staining). On the
other hand, homogeneous patterns with regular-shaped
nuclei were mainly represented in the cells incubated with
rat CM as well as in the control cells (Figure 8, upper and
middle row, DAPI staining). To examine whether Spalaxfibroblast CM could induce mitochondrial dynamic
changes in cancer cells, Hep3B cells were stained with
MitoTracker-Red® probe after eight days of incubation.
Compared with control and rat CM, the mitochondrial
network of cells after eight-day growth with Spalax CM
demonstrated the presence of damaged fragmented mito-
chondria (Figure 8, lower row, MitoTracker® + DAPI).
Similar to Hep3B cells, HepG2 cells under Spalax CM also
showed morphological changes and accumulation of cells
in sub-G0/G1 whereas mouse and rat CM did not affect
cellular morphology and cell cycle distribution (Figure 9).
BrdU incorporation into DNA, a marker for cell prolifera-
tion, confirmed a time-dependent anti proliferative effect of
Spalax CM on HepG2 cancer cells (Figure 9E).
Spalax normal fibroblasts inhibit colony formation in soft
agar of the breast carcinoma cell lines MDA-MB-231 and
MCF7 as well as Spalax-derived fibrosarcoma
To study whether soluble factors generated by Spalax
fibroblasts may influence colony formation in soft agar,
breast cancer cells were cultivated for three weeks in
the absence or presence of Spalax fibroblasts (Figure 10).
Spalax fibroblasts strongly reduced the formation of MDA-
MB-231 colonies (Figure 10A,B). The ability of MDA-MB-
231 to form large colonies was completely inhibited by
Spalax fibroblasts (Figure 10C), while rat fibroblasts had no
effect on colony formation (Figure 10A,B). Cells from
another human breast cancer cell line, MCF-7, were in-
cubated with monolayers of Spalax and mouse fibroblasts
(Figure 10D). Remarkably, after 11 days, and compared
to the control, more colonies were formed when human
MCF7 cells were co-cultured with mouse fibroblasts,
whereas a monolayer of Spalax fibroblasts significantly
reduced MCF7 colony-formation.
Importantly, Spalax normal fibroblasts suppressed
growth and colony formation of the homologous tumor,
Spalax-derived fibrosarcoma (SpFS2240) (Figure 11). In
contrast, both rat and mouse normal fibroblasts stimulated
growth of Spalax tumor cells in soft agar (Figure 11A).
Integrating the number of colonies and their total occupied
area, calculated from five independent fields, revealed
a 36% reduction when SpFS2240 were grown above a
Spalax fibroblast monolayer compared to blank plates
(Figure 11B, 2240 alone). In contrast, mouse and rat fibro-
blasts enhanced colony formation by factors of 1.7 and 2.1,
respectively, compared to the blank plates (Figure 11B).
Discussion
Notwithstanding the importance of laboratory mice
in comprehension of carcinogenesis mechanisms, this
cancer-prone model organism failed to provide satisfactory
knowledge of cancer preventive mechanisms and treatment
strategies in humans. (http://www.safermedicines.org/
quotes/cancer.shtml). Therefore, elucidating mechanisms
Figure 7 Effects of conditioned media (CM) on viability of cancerous and non-cancerous cells. (A) Hep3B cells were seeded in a 96-well
plate at a density of 5 × 103 and 1 × 103 cells/well in RPMI-DMEM/F12 medium conditioned by Spalax or mouse skin newborn fibroblasts
(SpNbF and MNbF, respectively). Hep3B cells were incubated for four days; viability was estimated by PrestoBlue® Reagent. (B,C) Hep3B cells
(1 × 104 cell/well) were cultured in six-well plates under conditioned medium of Spalax adult skin fibroblasts (B) or grown in medium generated
by Hep3B cells (C). After nine days, the cells’ survival rates were assessed by a Countess® cell counter (Life Technologies); red: dead cells, blue:
viable cells. (D) Hep3B and HepG2 cells were incubated under Spalax CM for four days, followed by changing the media either to fresh media or
new Spalax CM. After two days, viability was estimated by PrestoBlue® Reagent. (E) Spalax fibrosarcoma cells (SpFS2240) were incubated for three
or seven days in full medium or under CM of Spalax adult skin normal fibroblasts (SpAdF CM), Hep3B (Hep3B CM), Spalax fibrosarcoma
(SpFS2240 CM). Cell viability was evaluated by using PrestoBlue® reagent. Results are presented as percentage of control (SpFS2240 CM);
mean ± S.D. (F) Effects of CM generated by Spalax or mouse normal fibroblasts (SpNbF CM and MNbF CM, respectively) on the growth of
non-cancerous cells. The viability was estimated after four days by PrestoBlue® reagent; mean ± S.D. (G) Heat treatment of conditioned media.
Seven-day CM, generated by Spalax or rat fibroblasts, was heat-treated at 56°C for 10 minutes and 30 minutes prior to addition to Hep3B cancer
cells (2,000 cell/well) in 96-well plates. Cells were incubated for seven days followed by PrestoBlue® test. All results were obtained from three
independent experiments performed in three to six technical repeats.
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cancer-resistant raises promising opportunities.
Spalax has been thoroughly investigated at the Institute
of Evolution of Haifa University as a model for adaptationto environmental hypoxia (for example, [1,23]). During the
last decade a growing number of genes involved in hyp-
oxic response have been studied and exhibited Spalax-
specific features [4,11]. Directly related to this study on
Figure 8 Spalax fibroblast-conditioned medium compromises cell cycle, causes nuclear and mitochondrial fragmentation in Hep3B
cells. Hep3B cells were grown on cover slips under medium conditioned by Spalax or rat fibroblasts for seven days. Representative
phase-contrast images demonstrating morphological changes (×200) are depicted. Cells were harvested and stained with PI, and cell cycles were
analyzed by flow cytometry. Representative flow cytometry histograms of three independent experiments performed in duplicate are presented.
Hep3B cells were stained with MitoTracker®Red, fixed with formaldehyde and counterstained with DAPI. Representative fluorescence microscopy
images demonstrating nuclear and mitochondrial changes are present. White arrows point fragmented nuclei; empty arrows point chromatin
condensation. Scale bars represent 10 μm. PI, Propidium iodide.
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p53 favoring cell cycle arrest over apoptosis [24] and a
unique Spalax heparanase splice variant that was shown
to significantly decrease tumor size and metastatic activity
compared to native heparanase [9]. Furthermore, despite
the extremely long lifespan of Spalax (>20 years), even
after studying thousands of individuals for decades, we
have never observed animals that developed spontaneous
tumors, nor show any aging-related phenotypic changes.
In vivo studies of carcinogen-induced tumor
We report here that Spalax is resistant to two-stage
DMBA/TPA, and 3-MCA carcinogen treatments. DMBA/
TPA is commonly used to study malignant transformation,
resembling formation of human squamous cell carcinoma
[25]. A single dose of DMBA induced substantial oxidative
stress [26], and when followed by repetitive application
of TPA led to persistent inflammation supporting tumori-
genesis [17]. In the present study, mice treated with
DMBA/TPA initially developed benign papillomas, which
subsequently transformed to squamous cell carcinomas.In contrast, treatment of Spalax led to necrotic wounds,
which completely healed with no signs of malignancy.
The carcinogen 3-MCA is known to produce fibrosarco-
mas through persistent inflammation and reactive metab-
olites causing severe oxidative damage [27]. In our study,
100% of 3-MCA-injected mice and rats developed tumors
at the injection site within two to three and four to six
months, respectively. One year after 3MCA treatment no
Spalax animals showed any pathological process. How-
ever, 2 out of 6 old individuals (from a total of 12 animals)
developed benign fibrotic overgrowths after 14 and 16
months, respectively, and only one case of malignant
transformation in a >10 year-old Spalax animal was
recognized, 18 months after 3-MCA injection.
It is well established that oxidative stress drives tumor
progression and metastasis [28]. Thus, the mechanisms
that Spalax evolved to survive hypoxia might be related
to resistance to induced or spontaneous cancers. Spalax
have recently been shown to have higher levels of reactive
oxygen species (ROS) processing enzymes compared to
hypoxia-intolerant rodents [4]. Nrf2, a transcription factor
Figure 9 Effects of Spalax, mouse and rat conditioned media on morphology and cell cycle progression in HepG2 cells. HepG2 cells
were incubated under conditioned media for eight days; thereafter, cell morphology was documented using phase contrast microscopy,
harvested, stained with PI and analyzed by flow cytometry. Representative images (×200) and flow cytometry histograms are presented:
(A) control media; (B) rat CM; (C) mouse CM; (D) Spalax CM; (E) BrdU incorporation assay: HepG2 were grown in 96-well plates (2000 cells/well)
for four and seven days under Spalax-generated CM. BrdU Cell Proliferation ELISA (Exalpha) was used. Time-dependent decrease in cell
proliferation under Spalax-generated CM is depicted. CM, Conditioned media; PI, Propidium iodide.
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structure in Spalax. Whereas it is highly conserved among
most mammals [4], Spalax Nrf2 carries 27 specific amino
acid replacements, 6 within the Neh6-domain, which is
critical for stabilizing the protein under ambient oxida-
tive stress and for its transcriptional activity [29]. Studies
performed on Nrf2−/− mice have shown the essential
role of Nrf2 for detoxification of DMBA metabolites
and protection against DMBA-induced carcinogenesis
[30]. Unraveling the molecular mechanisms resulting
in the healing of Spalax skin and inhibition of progression
to tumor formation is the goal of our ongoing research.
Hence, we have just initiated a comprehensive repetition of
DMBA/TPA treatment where we will have a representative
sample of animals from different stages following the
application of this carcinogen in order to answer this
question through quantification of apoptosis and senes-
cence of Spalax skin and muscle tissue at the area of the
carcinogen application. Furthermore, considering the
high tolerance of Spalax to oxidative stress and the fact
that DMBA is metabolized among others into ROS that
cause oxidative DNA damage in the skin [31], the above
experiment will allow us to compare the ROS levels upon
DMBA application in Spalax and mice.
Another antioxidant enzyme, heme oxygenase-1 (HO-1),
was shown to be elevated in Spalax tissues, and further
increased under hypoxia [4,11]. HO-1 is involved in
the degradation and catabolism of heme and supportssynthesis of ferritin, an iron storage protein, thus preventing
oxidative damage caused by free heme and ROS [32].
Indeed, most Spalax individuals, showing no external
lesions following exposure to carcinogens, have probably
resolved the initial inflammatory insult without excessive
fibroplasias which can be attributed to more efficient anti-
oxidation mechanisms. The benign fibroblastic prolifera-
tions observed in two 3-MCA-treated Spalax animals after
14 and 16 months suggest that Spalax is able to effect-
ively arrest cancerous transformation. Nonetheless, whether
Spalax tissues are able to prevent conversion of the
3-MCA pro-carcinogen into an active carcinogen, over-
come its effect, or to inhibit previously transformed cells,
remains to be clarified in future studies.
In vitro studies of Spalax cancer resistance
Tumor growth and invasion are dependent on growth
factors and cytokines produced by stromal cells [33].
Normal stroma contains a relatively small number of fi-
broblasts associated with ECM. However, during wound
healing, fibrosis or malignant transformations, stromal
fibroblasts proliferate, intensively produce growth factors
and cytokines, express α-smooth muscle actin and become
cancer-associated fibroblasts (CAFs) [12,34,35]. CAFs are
removed from the granulation tissue rapidly after healing,
though in cancer stroma they persist, contributing to
epithelial mesenchymal transition of cancer cells. The
later phenomenon is important for cancer progression
Figure 10 Spalax fibroblasts suppress colony formation of human breast cancer cells MDA-MB-231 and MCF7 in soft agar. (A) MDA-MB-231
cells (5 × 103 cells) cells were suspended in 0.35% agar and added as the cancer cell top layer to base layer either empty (blank) or containing the Spalax
or rat fibroblast monolayer. At Day 21, colonies larger than 50 μm were counted under an inverted microscope and photographed (×40). Representative
microscopic images out of 15 fields are shown. (B) Average number of colonies counted in soft agar (n = 15). The experiment was performed in duplicate
plates at least three times; mean ± S.D. (C) A representative colony in soft agar was formed by MDA-MB-231 only, or by co-culturing with a Spalax
fibroblast monolayer. The size bar shows equivalent magnification in both images (× 200). (D) MCF7 cells (5 × 103 cells) were grown in soft agar on top of
a monolayer of mouse newborn (MNbF), or Spalax newborn fibroblasts (SpNbF) in 35-mm culture dishes. After 5 and 11 days of incubation colonies
containing >20 cells were counted by using an inverted microscope (× 200), mean ± S.D.
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secretion and ROS generation [36,37]. Although the
reports published to date have been mainly addressed
to a cancer-promoting role of stromal fibroblasts, evidence
suggests that normal stroma and normal fibroblasts could
impede tumorigenesis [14-16,38,39]. Early studies [15]
demonstrated that normal dermal fibroblasts suppressed
development of malignant phenotypes of RAS-transformed
keratinocytes when grafted into animals. Similarly, normal
fibroblasts were able to retard melanomagenesis in its early
stages [38]. Inhibition of growth and induction of differenti-
ation were found in breast cancer pre-neoplastic MCF10-
AT1-EIII8 cells when co-cultivated with normal fibroblasts,
even in the presence of estrogen [39]. It is still unclear what
events in the stroma, along with its interaction with precan-
cerous cells, lead to a transition of the stromal function
from cancer-protective to cancer-promoting, or, as in the
present case of Spalax, what are the molecular mechanisms
that Spalax evolved to escape cancerous transformation
and to develop anti-cancer ability.
In a recent study [40], cancer resistance in Spalax
was discussed. It was suggested that pro-growth signals
originating from the fetal bovine serum, routinelyadded to culture medium, are conceived as cancerous
transformation-like stimuli, driving Spalax fibroblast
necrotic death, triggered through release of interferon-β
(IFN-β). Nonetheless, in the same study, higher and
earlier death rates were also shown in serum-reduced
or serum-free media. Furthermore, the possibility that
CM from “dying” cells may lack beneficial nutrients, or
contain toxic metabolites, or other factors beyond IFN-β,
was not addressed. Additionally, measurements of IFN-β in
Spalax CM were performed indirectly using human cell
lines [40]. The first, VSV (Vesicular Stomatitis Virus)-GFP
(encoding a Green Fluorescent Protein) gene assay, mea-
sures IFN-β expression levels by VSV-GFP reporter assay.
In this assay, HT1080 cell line (human fibrosarcoma cells)
had been incubated with Spalax CM, and then infected
with a GFP-encoding VSV. The level of IFN-β in the media
corresponds to the reduction in the number of GFP
positive human HT1080 cells. In the second assay,
IFN-β release by “dying” Spalax cells is determined by
HEK (Human Embryo Kidney cells)-Blue cells assay. In
this assay the induction of β-gal reporter in human EK
cells under IFN-β-inducible promoter is measured. Both
assays use human cells for indirectly measuring Spalax
Figure 11 Effect of Spalax, rat and mouse fibroblasts on
Spalax-derived fibrosarcoma cells colony formation.
(A) SpFS2240 Cancer cells were grown in soft agar on top of
monolayers of mouse, rat and Spalax fibroblasts. After three weeks,
colonies were counted. At least 10 fields were recorded for each
observation. Two representative images demonstrating effects of
different fibroblasts on colony-formation are shown (×40).
(B) Colony numbers and cumulative total colony area (μm2) from five
fields were calculated to demonstrate the effects of the fibroblasts
monolayer on the cancer cell colony formation and growth.
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that human cells are nonresponsive to Spalax CM stimuli
possibly due to species divergence of IFN-β [40]. Likewise,
no proof was given that the ability to kill “dying” fibro-
blasts is unique to Spalax’s CM, for example, by trying tocompare the fate of the cells when grown with CM of the
other species tested in the study, namely, mice or human.
Additionally, the method used in this study for declaring
necrotic death is based on the Annexin V/propidium
iodide assay [40]. Briefly, floating and adherent cells were
harvested, stained with Annexin-V and propidium iodide,
and analyzed by flow cytometery. The known disadvan-
tage of this method is that it cannot conclusively prove
that cell death is solely the result of necrosis, nor eliminate
the possibility of apoptotic mechanisms. Also, the authors
have not provided evidence for interrelations between their
three declared observations (transformation-like stimuli,
necrotic death and release of IFN-β). Overall, it is our im-
pression that the above mentioned study [40] does not pro-
vide direct evidence to Spalax cancer resistance, certainly
not its anti-tumor properties. Alternatively, we show here
that viable, proliferating Spalax fibroblasts, from adult and
newborn animals, inhibit growth of cancer cells derived
from different tissues and species, most importantly hu-
man, but do not affect non-cancerous cells, including
those of Spalax (Figure 7F), thereby highlighting a strategy
used by Spalax to identify and target malignancies. This
unique interaction is further strengthened by the observa-
tion that the growth of cancer cells is regained once the
immediate interaction with Spalax cells is terminated
(Figure 7D). Importantly, no inhibitory effect on cancer
cell growth was found when fibroblasts from above-ground
species (rat, mice and Acomys) were tested.
Recently, several studies investigated the unique cancer-
resistance properties of the naked mole rat (Heterocephalus
glaber), another subterranean, long-lived, rodent species.
The most recent study suggested a connection between
a high viscosity of media conditioned by Heterocephalus
fibroblast cells due to exceptional secretion of high-
molecular mass hyaluronan (HMM-HA) [41], which was
suggested to mediate what was named by the authors “early
contact inhibition”, previously described by the same group
as an anticancer mechanism in Heterocephalus cells, and
was initially ascribed to p16(Ink4a) and p27(Kip1) activity
[42]. In the same paper [41], it is reported that HMM-HA
was detected also in Spalax fibroblasts even in higher levels
compared to Heterocephalus fibroblasts, though no experi-
ments were carried out to clarify its role in Spalax fibro-
blasts. Nevertheless, this may explain the prevalent high
viscosity of the medium of cultured Spalax fibroblasts we
noticed, though we find that it does not prevent Spalax
cells from reaching confluence or influences their anti-
cancer properties. Furthermore, CM from Spalax with
apparent normal viscosity was also able to inhibit cancer
cells proliferation (ongoing study). In light of the fact that
hyaluronan-cancer cell interactions were shown to pro-
mote, and not inhibit, cancer invasion [43], the correlation
between HMM-HA, the potential of cells to reach conflu-
ence and the resistance to oncogenic transformation or
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support, especially in the case of our model organism, the
Spalax. Another study endorsed Heterocephalus cells’
cancer-resistance to rapid cell crisis following oncogenic
transformation, which is characterized by abnormal
chromatin material and nuclei, leading to a failure to
successfully complete cell division, hence the inability
of the cells to progress into malignancy [44]. These
observations are somewhat similar to our findings of
fragmented and deformed nuclei and chromatin con-
densation (Figure 8), disturbed cell division and prolif-
eration (Figure 9E) of human cancer cells, as well as the
3MCA-induced Spalax and mice fibrosarcoma cell line,
upon their interaction with Spalax fibroblasts. In view
of the similar ability of Heterocephalus fibroblasts to kill
cancer cells (Figure 6), and as the efficiency of experimental
oncogenic transduction of cells is never 100%, it is possible
that the Heterocephalus cells that escaped malignant trans-
formation killed the oncogenic-transduced ones.
Our findings demonstrated that Spalax fibroblasts or
their CM target human cancer cells growth machinery,
triggering programmed cancer cell death (Figures 4, 5,
8 and 9). Following co-culture with Spalax fibroblasts
or their CM, cancer cells (Hep3B, HepG2 and MCF7)
undergo morphological changes typical of apoptosis [45]:
swelling, rounding, detachment, shrinkage and floating.
Moreover, nuclear condensation and abnormal mitochon-
drial fission as well as accumulation of cells in sub-G1
(Figures 8 and 9) also suggest apoptotic modes of cancer
cell death. BrdU incorporation, reflecting cell proliferation,
confirmed that Spalax CM contains anti-proliferative fac-
tors, inhibiting cell division in a time-dependent pattern.
We further showed that the effect of Spalax CM on cancer
cells is transient and reversible. That is, replacing the CM
with regular fresh medium leads to recovery of those cancer
cells that had not been affected by the CM. Last but not
least, Spalax fibroblasts presumably impair the aggressive
behavior of tumor cells: the invasive phenotype of highly
metastatic MDA-MB-231 breast carcinoma cells was
markedly reduced (Figure 10). Noteworthy, the ability
to form colonies in soft agar by 3MCA-induced, Spalax-
derived fibrosarcoma was significantly suppressed by
homologous fibroblasts, whereas heterologous fibroblasts
(rat and mouse) increased tumor formation (Figure 11).
Spalax fibroblasts also inhibited colony formation in
soft agar by 3MCA-induced, mouse-derived fibrosarcoma.
In order to strengthen our findings of Spalax cells’
anti-cancer activity, compared to cells from laboratory,
in-bred, aboveground mice and rats, we decided to follow
the cancer activity pattern of two other, wild, out-bred,
species. Hence, fibroblast cells were propagated from the
aboveground, wild, short-lived rodent Acomys, and the sub-
terranean, wild, long-lived Heterocephalus. We have shown
here that, similar to Spalax cells, Heterocephalus fibroblastsrestrict growth and effectively kill cancer cells, while
Acomys cells behave similarly to rat and mice, that is,
have no anti-cancer activity (Figure 6). We may assume
that this anti-cancer ability might be shared by species
living under extreme conditions and adapted to stress, such
as hypoxia, which is directly related to cancer initiation and
progression. It would be interesting to investigate this
phenomenon in other hypoxia-tolerant species, such as
other subterranean, high altitude and diving mammals.
Previous studies showed that key hypoxia-regulatory
genes in stromal fibroblasts, such as HIF1-α and VEGF,
negatively influence tumorigenesis [46]. HIF1-α is a known
tumor-promoting transcription factor in most malignancies
[47]; however, its expression in tumor stromal fibroblasts
could suppress cancer cell growth [46]. We have previously
shown that HIF1-α [23] as well as ROS-scavenging enzymes
[4] are constitutively highly expressed in Spalax. Similar to
our explanations of the failure to induce cancer in vivo
in live Spalax animals, in vitro studies, using fibroblast
cells, demonstrated a significant role in adaptive response
to oxidative stress, at least in part, via expression of HO-1
[48]. High levels of mitochondrial ROS produced by cancer
cells were shown to drive tumor development via remodel-
ing of the stromal environment and enhancing invasion.
Recently, the roles of ROS produced by fibroblasts in their
trans-differentiation to myofibroblasts and in cancer
cell invasiveness were reported [37]. ROS-generating CM of
mutated fibroblasts promoted metastasis of A375 melanoma
through the increasing of ROS and HIF1-α stabilization in
melanoma cells. However, when N-acetyl cysteine, a ROS
scavenger, was added to the system, HIF1-α accumulation
and melanoma cell invasion were inhibited [37].
Adaptive tolerance to hypoxia stress in Spalax, both
in vivo and in vitro, may grant the unique resistance to
cancer through strong antioxidant mechanisms, among
others (for example, as mentioned here, the unique activity
of its p53 [8] and heparanse [9]), that quench ROS before
they spread and damage DNA and other macromolecules,
thus providing cellular homeostasis and cancer protection.
As such, they are a milestone in our efforts in understand-
ing the mechanisms by which the long-lived, hypoxia-
tolerant Spalax hinders cancer initiation and progression.
Collectively, we have shown here an outstanding cancer
resistance of the whole, live Spalax, and not just in cultured
cells, and anticancer activity of Spalax cells on human
cancer cells, and not just resisting transformation of its
own healthy cells. This phenomenon extensively described
here using different methodologies on cells from different
ages of Spalax, together with our initial observation of a
similar ability of cells originated from another subterra-
nean, long-lived, hypoxia- and cancer-resistant animal, the
Heterocephalus, highlight the importance to adopt such
animal models with exceptional genetic-embedded tolerance
to environmental stress, in cancer research.
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factors secreted by Spalax cells, and their selective
interaction with cancer cells to suppress tumorigenesis. Our
first step to exploring the nature of the secreted factors was
the heat-inactivation preliminary experiment presented here
(Figure 7G). The heat treatment of Spalax CM caused only
partial loss of the anti-cancer activity of Spalax-generated
CM. Although not conclusive, this may indicate the in-
volvement of protein factors in the observed phenomenon.
We are also studying the signaling mechanisms and death
receptors whose activation triggers cancer cell death. These
studies will hopefully contribute to the identification of new
anti-cancer mechanisms and future tumor preventive or
therapeutic strategies. To our knowledge, the present study
demonstrates, for the first time, Spalax tolerance to chem-
ically induced carcinogenesis along with direct anticancer
effect of Spalax fibroblasts on human cancer cells.
Conclusions
During 50 years of studies, with thousands of animals
that crossed our Animal House, we have never observed
spontaneous tumors in Spalax. Similar phenomenon
was observed also in another subterranean long-lived
rodent, Heterocephalus. Based on this observation, a few
studies [41,42,44] have tried to explain cancer resistance in
Heterocephalus through testing known molecular mecha-
nisms of malignant transformation on healthy fibroblast
cells. Though different molecular mechanisms were
suggested, none of these studies dealt with anti-cancer
properties of the whole, live animal in vivo, or on the
direct interaction of its normal cells with cancer cells.
Hence, our presentation is a pioneering, genuine, break-
through study. We have tried to induce cancer in Spalax
with chemical carcinogens that induced cancer in 100% of
mice and rats, and the results allow us to state that Spalax
is extremely resistant not only to spontaneous cancer but
also to induced cancer. Furthermore, fibroblast cells from
Spalax inhibit growth and kill cancer cells from vari-
ous species and cell lines. This is exhibited in both the
co-culture system or by exposure to conditioned media
harvested from Spalax fibroblasts. Cancer cell death was
accompanied by decreased cancer cell viability and prolifer-
ation, reduced colony formation in soft agar, disturbed cell
cycle progression, chromatin condensation, nuclei deform-
ation and mitochondrial fragmentation.
This phenomenon is prominent in Spalax fibroblasts,
regardless of the animal age, from newborns a few days old
to animals over 10 years old, as proved by the reversibility
of cancer cells death, once their immediate interaction with
Spalax fibroblasts is terminated. The anti-cancer activity of
Spalax is specific to cancer cells and not to normal cells. It
may be shared by other stress-adapted mammals as we ini-
tially showed here by co-culturing Heterocephalus fibro-
blasts with cancer cells that also leads to cancer cell death.“The classical mice model for cancer research has little
predictive value and a negligible relation to that of human.
Far more than anything else, the lack of good animal
models has become the rate-limiting step in human cancer
research” (Prof. Robert Weinberg, MIT; Newsweek,
September 6th, 2008). Therefore, it would be extremely
useful to study naturally cancer-resistant animals, as models
to find ways to prevent cancer before it occurs. Our results
may lead to a breakthrough in the conservative paradigm
of cancer research, completely dependent on laboratory, in-
bred rodents, and place Spalax as the ‘missing’, appropriate
candidate model for such studies. We anticipate that the
long lived, hypoxia- and cancer-tolerant Spalax will turn
out to be a significant biological resource to biomedical




All animal protocols were approved by the Institutional
Ethics Committee.
Blind mole-rat (Spalax), rats (Rattus norvegicus) and
C57BL/6 mice were subjected to DMBA/TPA or 3MCA
treatments. For DMBA/TPA treatment, eight Spalax and
six mice were used. For 3MCA treatment 12 Spalax, 6 mice
and 6 rats were used. Spalax and Acomys were captured in
the field and housed under ambient conditions in individual
cages in the Animal Facility of the Institute of Evolution,
University of Haifa. Noteworthy, Spalax do not undergo
uniform acclimatization upon transfer from their natural
habitat to a standardized laboratory environment but rather
behave differentially according to their eco-geographic
origins [49]. The C57BL/6 mice were purchased from
Harlan Laboratories (Jerusalem, Israel). Rats were supplied
by the Animal House of the Psychology Department of
Haifa University. Heterocephalus was a gift from Tisch
Family Zoological Gardens in Jerusalem. All animals were
kept with free access to food and water at 21 to 23°C in a
12:12 light-dark cycle. All animals used for experiments
were healthy. Animals were sacrificed with an inhalation
anesthesia agent (isoflurane) overdose.
DMBA/TPA treatment
Four Spalax individuals approximately 2 years old and
four individuals over 10 years old; and six individuals of
C57BL/6 mice, 3 to 4 months old, were used in the 7,12-
Dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-
13-acetate (DMBA/TPA) experiments. A single application
of 200 μg of DMBA dissolved in 100 μl of acetone for mice,
and 500 μg in 250 μl for Spalax was used. The solution was
applied onto the shaved back skin of the animal. Three days
after the initial DMBA dose, mice were treated with 30 μg
of TPA (Sigma Aldrich, Inc.) dissolved in 100 μl of acetone,
and Spalax with 60 μg of TPA dissolved in 250 μl of
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three months, until all mice developed advanced cancer
and were subsequently sacrificed. Spalax continued to be
treated for an additional three months twice a week.
3-MCA carcinogen treatment
3-methylcholanthrene (3-MCA) has been commonly used
for induction of tumors in rodents [50]. In this experimental
system, mice and rats develop local fibrosarcomas in
two to three and four to six months, respectively [20].
The recommended dose of 3MCA (Sigma Aldrich, Inc.)
for treatment of mice is 200 μg dissolved in 200 μl of olive
oil [20,51]. We calculated the amount applied to rats and
Spalax according to their average weight. Hence, animals
were treated with a single injection of 3MCA as follows:
200 μg/200 μl for mice; 1 mg/500 μl for Spalax; and 1.5
mg/500 μl for rats. Animals used in this experiment were:
six approximately 2-year-old Spalax individuals; six 10-year
old or older Spalax individuals; six 3- to 4- month-old mice;
and six 3-month-old white rats. Animals were observed
once a week until tumors could be palpated, and then two
to three times a week. Animals were sacrificed; tissues were
removed for cell isolation or fixation. For histological exam-
ination, the samples were fixed in 4% paraformaldehyde
dissolved in PBS, dehydrated in increasing concentrations of
ethanol, and embedded in paraffin. Five-micrometer sec-
tions were cut from paraffin blocks and routinely stained
with hematoxylin and eosin for microscopic examination.
Cell culture
Primary Spalax, mice, rat, Acomys and Heterocephalus
fibroblasts were isolated from under arm skin and lungs
as described [52], and grown in DMEM-F12 medium
(Biological Industries, Beit Haemeq, Israel), supplemented
with 15% fetal bovine serum (FBS). Human cancer cell lines
Hep3B and HepG2 (hepatoma-derived), MCF7 and MDA-
MB-231 (breast cancer cells) were obtained from ATCC,
and were grown in RPMI (Hep3B, HepG2) and DMEM
(MCF7, MDA-MB-231) supplemented with 10% FBS,
L-glutamine, penicillin and streptomycin (Biological
Industries). Cells were incubated in a humidified atmos-
phere of 5% CO2 and 95% ambient air at 37°C. Spalax-
derived fibrosarcoma cells were isolated from a tumor
developed after 3MCA injection. Tumor specimens
were minced and treated with 1 mg/ml of collagenase
(Sigma-Aldrich) under aseptic conditions to obtain a
single-cell suspension, which was plated in culture dishes in
DMEM-F12 medium supplemented with 15% FBS and
penicillin-streptomycin-amphotericin B solution. Cells were
serially cultured more than 40 times.
Co-cultures of cancer cells and fibroblasts
Normal fibroblasts and human-derived cancer cells were
co-plated in six-well plates in 2 ml of culture mediumRPMI or DMEM/DMEM-F12 (1:1) supplemented with
15% FBS. Fibroblasts were plated first (5 × 104), and
cancer cells were added within 1 h (5 × 103), with a
10:1 fibroblast-to-cancer cell ratio. In parallel, control
cultures of cancer cells and fibroblasts were plated at
the same number of cells. The medium was changed
every three days. Fibroblast-cancer cell co-interactions
were observed and photographed by using an inverted
microscope (Optika XDS2, Italy).
Generation of conditioned media
Normal fibroblasts or cancer cells (1 × 106 cells) were
plated in 10-cm tissue culture dishes and cultured in
full medium containing 10% FBS for four days; there-
after, media were collected and cells were removed by
centrifugation. The cell-free supernatants were then diluted
with the appropriate fresh culture medium (1:1) and used
for further experiments. Trypan-blue standard treatment
followed by cell count using a Countess® automatic cell
counter (Life Technologies), and PrestoBlue® dye reagent
(Invitrogen) (as described in [53]) were used to investigate
the viability of cancer cells exposed to CM of normal fibro-
blasts from different species. For BrdU incorporation assay,
Cell Proliferation ELISA (Exalpha) was used following the
manufacturer’s instruction.
Soft agar colony formation assay
Colony formation assay was performed as described [54].
In brief, 2 × 105 fibroblasts were seeded in 35-mm culture
dishes and cultured for two to three days to reach con-
fluence. After washing with PBS, 1 ml of 0.5% agar in
DMEM-F12 containing 2% FBS was added on top of the fi-
broblasts to form a base layer. After the agar was solidified,
5 × 105 cancer cells were suspended in 1 ml of 0.35% agar
in DMEM containing 5% FBS and then added into the dish
to form a cancer cell layer. Visible colonies were studied
and photographed under phase-contrast microscope.
Finally, colonies larger than 50 μm were counted. At least
10 fields on each plate duplicate were used for counting at
a magnification of × 40. For total colony area, five fields
were analyzed using ImageJ software [55].
Cell cycle analysis
The cell cycle distribution was assessed by flow cytometry
of propidium iodide (PI)-stained nuclei as described
previously [56]. In brief, following incubation, cells were
harvested by trypsin, combined with medium containing
floating cells, washed with PBS and stained with hypotonic
PI solution (PI 50 μg/ml in 0.1% sodium citrate and 0.1%
Triton X-100). The PI fluorescence of individual nuclei was
recorded by FACSaria (Becton Dickinson, NJ, USA). A total
of 10,000 events were acquired and corrected for debris
and aggregate population.
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Cells grown on cover slips were stained with
MitoTracker®Red CM-XRos (Life Technologies) at 37°C in
a humidified 5% CO2 atmosphere for 15 minutes and fixed
with 3.7% formaldehyde in culture medium for another 15
minutes at 37°C. After washing with PBS twice, nuclei were
counterstained with DAPI. Images were acquired with
a fluorescence microscope.
Transmission electron microscopy
For transmission electron microscopy, specimens were
fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer (pH 7.2), postfixed with 2% OsO4, dehydrated in
ethanol series and embedded in epoxy resin. Semi-thin
sections were stained with 1% Toluidine Blue. Ultrathin
sections (60 nm) were cut with a diamond knife, placed
on 300-mesh copper grids, stained with 1% uranyl acetate,
and viewed and photographed with a transmission electron
microscope (Technai T12, FEI).
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